Please ensure Javascript is enabled for purposes of website accessibility

3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata

By Brian Orelli, PhD – Feb 14, 2014 at 12:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A video looking at upcoming FDA decisions for Chelsea Therapeutics, MannKind, and Durata Therapeutics.

In a recent slideshow on one-drug wonders, Fool Brian Orelli pointed to three companies that have been very successful after launching their first major drug.

In the video below, he talks with Max Macaluso, the Fool's health care bureau chief, about three companies: Chelsea Therapeutics (NASDAQ: CHTP), MannKind (MNKD 1.81%), and Durata Therapeutics (NASDAQ: DRTX), which are looking to launch their first drug if the FDA agrees.

Chelsea Therapeutics is on its second attempt to have its low blood pressure medication Northera approved. MannKind is on its third attempt for its inhaled insulin Afrezza. And Durata Therapeutics is up for an FDA approval for its antibiotic Dalvance.

 

Brian OrelliMax Macaluso, and The Motley Fool have no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.51 (1.81%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.